December 09, 2025

Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer

In individuals younger than age 50 undergoing a colonoscopy, greater odds for having colorectal cancer were observed among those who presented with rectal bleeding, according to findings from a study ...

The ASCO Post

December 09, 2025

AACI Issues Statement on Death of Dr. Ed Chu

The Association of American Cancer Institutes (AACI) offered a statement on the death of Dr. Ed Chu. Portions of that statement are provided here.

The ASCO Post

December 09, 2025

Montefiore Einstein Comprehensive Cancer Center Director, Physician Scientist, Edward Chu, MD, MMS, Dies at 66

Albert Einstein Collegeof Medicine and Montefiore Einstein Comprehensive Cancer Center shared news of the death of the Cancer Center’s Director, Edward Chu, MD, MMS, on November 13, 2025. The cause of...

The ASCO Post

December 09, 2025

Validation of Pathology-AI Integration Tool for Risk Stratification in Locally Advanced Colon Cancer Without Chemotherapy

The Combined Analysis of Pathology and Artificial Intelligence (AI; CAPAI) model effectively stratified patients with colon cancer into distinct prognostic groups, identifying nearly half as low-risk,...

The ASCO Post

December 05, 2025

Zanzalintinib Plus Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer

The phase III STELLAR-303 trial evaluated the anti-VEGFR–related multitargeted tyrosine kinase inhibitor zanzalintinib in combination with the PD-L1 inhibitor atezolizumab vs the multikinase inhibitor...

The ASCO Post

January 01, 0001

Assessment of Pathologic Response in Patients With Locally Advanced Rectal Cancer: Implications of the Park et al. Study

A landmark study reveals the critical role of neoadjuvant chemoradiotherapy in locally advanced rectal cancer treatment, underscoring the importance of treatment response evaluation for better patient outcomes.

JADPRO

January 01, 0001

Ziv-Aflibercept Use in Metastatic Colorectal Cancer

Colorectal cancer remains a leading global health challenge, with advancements in targeted therapies like ziv-aflibercept offering new hope alongside traditional treatments.

JADPRO

January 02, 2025

FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indicatio...

The ASCO Post

August 02, 2023

Gastrointestinal Symptoms May Be Prevalent in Geriatric Female Colorectal Cancer Survivors

About 80% of geriatric female colorectal cancer survivors may experience a range of gastrointestinal symptoms years after receiving a diagnosis and treatment for their tumors, according to a recent st...

The ASCO Post